Gabapentin Capsule
Product Images NDC 45865-216

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45865-216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

216 (45865 216)

Label for Gabapentin capsules 100 mg, generic for Neurontin, manufactured by ACI Healthcare USA. The label indicates a quantity of 30 capsules, each white and oblong. It includes warnings about dizziness, drowsiness, and avoiding alcohol. Distributed by Medsource Pharmaceuticals.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A text panel showing a formula for calculating creatinine clearance (CLCr), which involves age, weight, serum creatinine, and an adjustment factor for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of Gabapentin showing its cyclohexane ring attached to amine and carboxyl functional groups.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, while the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, showing a decreasing pain score trend for Gabapentin compared to placebo.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo and gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis represents time in weeks, and the y-axis represents mean pain score from 0 to 10. The graph shows a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' compares placebo (PBO) versus Gabapentin (GBP) doses in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg; Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated as p < 0.01 and p < 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart depicting the difference in percentage (%) on the vertical axis versus daily dose in milligrams (mg) on the horizontal axis. It compares results from three different studies labeled as STUDY a, STUDY b, and STUDY c, with data points at doses of 600, 900, 1200, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.